CROI 2022: tuberculosis and infectious complications in persons With HIV.

Q1 Medicine Topics in antiviral medicine Pub Date : 2022-10-01
Andrew D Kerkhoff, Diane V Havlir
{"title":"CROI 2022: tuberculosis and infectious complications in persons With HIV.","authors":"Andrew D Kerkhoff,&nbsp;Diane V Havlir","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Early treatment of anal high-grade squamous intraepithelial lesions compared with active monitoring reduced the risk of anal cancer by 57% in persons with HIV in a landmark randomized trial of 4446 participants. In a multi- country randomized trial, an entirely oral combination regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin for 24 weeks outperformed the World Health Organization-recommended 36- to 96-week standard of care regimen for multidrug-resistant tuberculosis (TB), ushering in a new era of shorter multidrug-resistant TB treatment. These and other studies of TB and coinfections in persons with HIV presented at the 2022 Conference on Retroviruses and Opportunistic Infections pro vided new insights and are summarized herein.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473896/pdf/tam-30-528.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Topics in antiviral medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Early treatment of anal high-grade squamous intraepithelial lesions compared with active monitoring reduced the risk of anal cancer by 57% in persons with HIV in a landmark randomized trial of 4446 participants. In a multi- country randomized trial, an entirely oral combination regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin for 24 weeks outperformed the World Health Organization-recommended 36- to 96-week standard of care regimen for multidrug-resistant tuberculosis (TB), ushering in a new era of shorter multidrug-resistant TB treatment. These and other studies of TB and coinfections in persons with HIV presented at the 2022 Conference on Retroviruses and Opportunistic Infections pro vided new insights and are summarized herein.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CROI 2022:艾滋病毒感染者的结核病和感染并发症。
在一项4446名参与者的具有里程碑意义的随机试验中,与主动监测相比,早期治疗肛门高级鳞状上皮内病变可使艾滋病毒感染者患肛门癌的风险降低57%。在一项多国随机试验中,由贝达喹啉、普雷托马奈、利奈唑胺和莫西沙星组成的全口服联合治疗方案持续24周,优于世界卫生组织推荐的36至96周耐多药结核病标准治疗方案,开创了一个更短时间耐多药结核病治疗的新时代。在2022年逆转录病毒和机会性感染会议上提交的这些和其他关于艾滋病毒感染者结核病和合并感染的研究提供了新的见解,并在此进行总结。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Topics in antiviral medicine
Topics in antiviral medicine Medicine-Pharmacology (medical)
CiteScore
1.80
自引率
0.00%
发文量
10
期刊最新文献
CROI 2024: Global Epidemiology and Prevention of HIV and Other Sexually Transmitted Diseases. CROI 2024: Metabolic and Other Complications of HIV Infection. CROI 2024: Summary of Basic Science Research in HIV. CROI 2024: Tuberculosis, Mpox, and Other Infectious Complications in People With HIV. Long-Term Effects of COVID-19: The Stories of 2 Physicians Who Became Patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1